Final outcome, immunophenotypic and biomarker analysis of intercalated avelumab plus platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (PAVE): A pilot phase II study of the Hellenic co-operative oncology group

Mountzios, G., Papadopoulou, K., Korfiatis, N., Goussia, A., Samantas, E., Aravantinos, G., Christopoulou, A., Spathas, N., Fountzilas, E., Psyrri, A., Koliou, G.-A., Kosmas, E., Bobos, M., Charchanti, A., Vamvakaris, I., Koumarianou, A., Bafaloukos, D., Kosmidis, P., Fountzilas, G., & Linardou, H. (2024). Final outcome, immunophenotypic and biomarker analysis of intercalated avelumab plus platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (PAVE): A pilot phase II study of the Hellenic co-operative oncology group. ESMO Open, 9, 102770. https://doi.org/10.1016/j.esmoop.2024.102770

Περίληψη

Extensive stage small cell lung cancer (ES-SCLC) is a poor prognosis disease, and first-line chemo-immunotherapy is now the standard-of-care. We hypothesized that intercalated administration of immunotherapy after two induction chemotherapy cycles, at maximal neoantigen release, might enhance immune response and overall efficacy.

DOI
10.1016/j.esmoop.2024.102770
Τύπος
Άρθρο σε Περιοδικό
Έτος
2024

Σύνδεσμοι

BibTeX

@article{mountzios2024final,
title = {Final outcome, immunophenotypic and biomarker analysis of intercalated avelumab plus platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (PAVE): A pilot phase II study of the Hellenic co-operative oncology group},
author = {Giannis Mountzios and Kyriaki Papadopoulou and Nikolaos Korfiatis and Anna Goussia and Epaminontas Samantas and Gerasimos Aravantinos and Athina Christopoulou and Nikolaos Spathas and Elena Fountzilas and Amanda Psyrri and Georgia-Angeliki Koliou and E. Kosmas and Mattheos Bobos and Antonia Charchanti and Ioannis Vamvakaris and Anna Koumarianou and D. Bafaloukos and P. Kosmidis and George Fountzilas and Helena Linardou},
url = {https://doi.org/10.1016/j.esmoop.2024.102770},
doi = {10.1016/j.esmoop.2024.102770},
year  = {2024},
date = {2024-01-01},
journal = {ESMO Open},
volume = {9},
pages = {102770},
publisher = {Elsevier BV},
abstract = {Extensive stage small cell lung cancer (ES-SCLC) is a poor prognosis disease, and first-line chemo-immunotherapy is now the standard-of-care. We hypothesized that intercalated administration of immunotherapy after two induction chemotherapy cycles, at maximal neoantigen release, might enhance immune response and overall efficacy.},
note = {Conference abstract 197MO},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

« Όλες οι δημοσιεύσεις